Indiana-based DePuy Orthopaedics, Inc. has promoted Andrew Ekdahl to be its new president. He replaces David Floyd, who left the company at the end of March.
Ekdahl Promoted to DePuy Orthopaedics President
1 min read Premium comments
Ekdahl is no stranger to DePuy. He joined the company over 20 years ago and has worked on orthopedics, trauma, sports medicine, neurosciences and spine. Prior to his new appointment, he was Franchise Vice President, DePuy Europe, Middle East and Africa. He had held positions in sales, marketing and distribution in the U.S., Canada and abroad.
He received his undergraduate degree in Economics from the University of Manitoba and his MBA from Wilfred Laurier University, both in Canada.
DePuy Orthopaedics, headquartered in Warsaw, Indiana, makes devices for the hip, knee, extremities and trauma, as well as bone cement and operating room products. Having served DePuy in Europe, he should be well situated to help DePuy and Synthes integrate over the coming months. One of his challenges will be to rebuild DePuy’s hip business, which saw an erosion of market share to its cross-town rival, Zimmer, due in part to the metal-on-metal ASR hip system recall in 2010. The company regained some of that market share in the first quarter of 2011. In knees, the company gave up some market share in the first quarter.
In his role as president, Ekdahl will serve on the DePuy Franchise Global Management Board of the DePuy Family of Companies of Johnson & Johnson.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.